NZ267220A - use of a retinoic acid to inhibit the production of tumour necrosis factor or nitric oxide - Google Patents

use of a retinoic acid to inhibit the production of tumour necrosis factor or nitric oxide

Info

Publication number
NZ267220A
NZ267220A NZ267220A NZ26722094A NZ267220A NZ 267220 A NZ267220 A NZ 267220A NZ 267220 A NZ267220 A NZ 267220A NZ 26722094 A NZ26722094 A NZ 26722094A NZ 267220 A NZ267220 A NZ 267220A
Authority
NZ
New Zealand
Prior art keywords
retinoic acid
production
nitric oxide
necrosis factor
tumour necrosis
Prior art date
Application number
NZ267220A
Other languages
English (en)
Inventor
Bharat B Aggarwal
Kapil Mehta
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of NZ267220A publication Critical patent/NZ267220A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NZ267220A 1993-05-17 1994-05-05 use of a retinoic acid to inhibit the production of tumour necrosis factor or nitric oxide NZ267220A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/061,471 US5457129A (en) 1993-05-17 1993-05-17 Inhibition of nitric oxide production by retinoic acid
PCT/US1994/004950 WO1994026277A1 (en) 1993-05-17 1994-05-05 Inhibition of tumor necrosis factor and nitric oxide production by retinoic acid

Publications (1)

Publication Number Publication Date
NZ267220A true NZ267220A (en) 2000-08-25

Family

ID=22036008

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ267220A NZ267220A (en) 1993-05-17 1994-05-05 use of a retinoic acid to inhibit the production of tumour necrosis factor or nitric oxide

Country Status (17)

Country Link
US (2) US5457129A (ja)
EP (2) EP0708648B1 (ja)
JP (2) JPH08510727A (ja)
KR (1) KR100345255B1 (ja)
AT (1) ATE228363T1 (ja)
AU (1) AU697072B2 (ja)
CA (1) CA2162990A1 (ja)
DE (1) DE69431801T2 (ja)
DK (1) DK0708648T3 (ja)
ES (1) ES2187522T3 (ja)
IL (1) IL109458A (ja)
NZ (1) NZ267220A (ja)
PT (1) PT708648E (ja)
SA (1) SA94150042B1 (ja)
TW (1) TW261529B (ja)
WO (1) WO1994026277A1 (ja)
ZA (1) ZA943320B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741774A (en) * 1993-11-12 1998-04-21 Trega Biosciences, Inc. Use of a cytokine regulatory agent to treat rheumatoid arthritis
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
FR2735371B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Procede pour identifier des composes antagonistes des recepteurs rars
FR2767058B1 (fr) * 1997-08-05 2000-05-05 Centre Nat Rech Scient Utilisation d'un compose de type retinoide, notamment l'acide retinoique pour la preparation d' un medicament destine au traitement de l'obesite.
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
WO1999011787A1 (fr) * 1997-09-02 1999-03-11 Sumitomo Pharmaceuticals Company, Limited ADN PARTICIPANT A LA REGULATION DE L'EXPRESSION DU GENE PEBP2αA, ET UTILISATION DE CET ADN
US6596500B1 (en) * 1998-12-08 2003-07-22 The General Hospital Corporation Binding of retinoids to M6P/IGF-II receptor
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6184246B1 (en) 1999-07-30 2001-02-06 The United States Of America As Represented By The Secretary Of Agriculture Inhibition of cytokine production by polymethoxylated flavones
AU7895000A (en) * 1999-10-19 2001-04-30 Kevin C Kain Products and methods for activating ppargamma-rxr and up-regulating monocyte/macrophage cd36 for the treatment of malaria
WO2002058586A2 (en) * 2001-01-26 2002-08-01 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
JP2004020220A (ja) * 2002-06-12 2004-01-22 Pioneer Electronic Corp 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム
US7071228B2 (en) * 2002-10-23 2006-07-04 Parks L Dean Method of treating musculoskeletal and connective tissue inflammations
WO2006088747A2 (en) * 2005-02-14 2006-08-24 Mercer University Serum-free reagents for the isolation, cultivation, and cryopreservation of postnatal pluripotent epiblast-like stem cells
US20110081410A1 (en) * 2005-06-28 2011-04-07 St. Marianna University, School Ofmedicine Therapeutic agent for local inflammation
US20080027031A1 (en) * 2006-03-08 2008-01-31 Kinemed, Inc. Retinoids and Related Compounds for the Treatment of Neuroinflammatory Conditions, Diseases and Disorders
WO2011038537A1 (zh) * 2009-09-29 2011-04-07 上海南方基因科技有限公司 败血症以及败血症休克的预测、预防和治疗方法及试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200647A (en) * 1977-12-21 1980-04-29 Hoffmann-La Roche Inc. Vitamin A compositions to treat rheumatic disease
AU558002B2 (en) * 1981-07-14 1987-01-15 Scotia Holdings Plc Enhancement of 1 series pg production using retinol or carotenoids and linolenic acid
US5264578A (en) * 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
EP0397774A1 (en) * 1988-02-04 1990-11-22 Board Of Regents, The University Of Texas System Formulation and use of retinoids in treatment of cancer and other diseases
US5157046A (en) * 1988-11-29 1992-10-20 Janssen Pharmaceutica N.V. Method of treating epithelial disorders
US5190876A (en) * 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
JPH051100A (ja) * 1990-07-11 1993-01-08 Teijin Ltd 腫瘍壊死因子活性抑制物質及びその製造方法
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
DK0567566T4 (da) * 1991-01-18 2007-10-22 Amgen Inc Fremgangsmåder til behandling af tumornekrosefaktor-medierede sygdomme
WO1993001211A1 (en) * 1991-07-05 1993-01-21 Peptide Technology Limited Peptide which abrogates tnf and/or lps toxicity
CA2129831A1 (en) * 1992-02-11 1993-08-19 Roshantha A. S. Chandraratna Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity

Also Published As

Publication number Publication date
KR100345255B1 (ko) 2002-11-30
JP2005263808A (ja) 2005-09-29
ES2187522T3 (es) 2003-06-16
DK0708648T3 (da) 2003-03-03
ATE228363T1 (de) 2002-12-15
EP0708648A4 (en) 1998-01-14
TW261529B (ja) 1995-11-01
WO1994026277A1 (en) 1994-11-24
EP0708648A1 (en) 1996-05-01
US5658949A (en) 1997-08-19
AU697072B2 (en) 1998-09-24
PT708648E (pt) 2003-04-30
ZA943320B (en) 1995-11-16
IL109458A0 (en) 1994-07-31
IL109458A (en) 2001-11-25
SA94150042B1 (ar) 2006-06-17
EP1243264A3 (en) 2002-11-06
JPH08510727A (ja) 1996-11-12
KR960702311A (ko) 1996-04-27
EP1243264A2 (en) 2002-09-25
DE69431801D1 (de) 2003-01-09
CA2162990A1 (en) 1994-11-24
DE69431801T2 (de) 2003-09-11
US5457129A (en) 1995-10-10
AU6944194A (en) 1994-12-12
EP0708648B1 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
NZ267220A (en) use of a retinoic acid to inhibit the production of tumour necrosis factor or nitric oxide
AU565720B2 (en) Applying surgical fasteners
AU8142594A (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
AU582584B2 (en) N-acetyl-neurominic acid expectorants
Blatner Theoretical principles underlying creative arts therapies.
WO1995003809A3 (en) Use of glucokinase inhibitors for the manufacture of a medicament for treating tumours
ES2122717T3 (es) Procedimiento y dispositivo para reducir el contenido en nitrato del agua.
NZ237513A (en) Retinoic acid esters, preparation and pharmaceutical/cosmetic compositions thereof
ES465291A1 (es) Procedimiento para preparar esteres de acidos ciclopropano- carboxilicos con alcoholes bencilicos halogenados.
George Other infections of skin, soft tissue, and muscle.
PL334093A1 (en) Application of comt inhibitors in production of drugs preventing occurence of vascular disorders in case of diabetes
FR2168202A1 (en) Accelerator for depilation - contg n vinyl lactam copolymer with unsatd carboxylic semi ester
ATE108181T1 (de) Substituierte (chinolin-2-yl-methoxy)phenyl- carbonyl-harnstoffe.
JPS54882A (en) Manufacture of field effect transistor
JPS5219852A (en) Spring washer
JPS52138586A (en) Anaerobic compositions having improved breaking torque strength
KR910007540A (ko) 혈구 감소 장해의 예방ㆍ치료제
JPS52143543A (en) Manufacturing system of wave-like fin
JPS52131529A (en) Production of ureidomethylenemalonic ester
JPS5382742A (en) Purification of arom.
JPS52133918A (en) Optically active beta-amino acid and its preparation
JPS5414964A (en) Production of 2,3-dihydrofuran
JPS5411292A (en) Immobilized material having enzymatic activity and its preparation
USD202551S (en) Insulated fastener for electronic component
FiJ et al. Liquid gold: low-osmolality contrast media

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired